The stem cell alopecia treatment market is set to grow at a compounded annual growth rate (CAGR) of 5.1% during the forecast period from 2018 to 2026. According to the research findings of the National Institute of Health (NIH), the global prevalence rate of androgenic alopecia is 15.33% and is highly variable according to geographical region.
It is highly prevalent in the Caucasian population and is reported to be a genetic anomaly. Currently, the U.S. Food and Drug Administration has approved only two drugs to treat alopecia: minoxidil and finasteride, both of which have demonstrated excellent therapeutic efficacy but are associated with severe adverse events. There is tremendous scope for stem cell technology to create regenerative medicine to address androgenic alopecia by employing human adipose tissue and umbilical cord embryonic mesenchymal stem cells.
Market Synopsis
The increasing deregulation of KRT37 by androgens as a result of hormonal and nutritional imbalance drives the growth of the male pattern baldness market.
Male pattern baldness is the most common indication for stem cell alopecia treatment. It is the most common type of hair loss in men throughout the globe, affecting 80% of the Caucasian population. As per the research cited by the U.S. National Library of Medicine (NLM), more than 50% of men over the age of 50 suffer from hair loss to some extent. The main culprits are increased androgen deregulation of KRT37 caused by hormonal and nutritional imbalances in men.
Female pattern baldness has garnered tremendous attention in the last decade on account of increasing socio-economic burden, depression, and anxiety in women suffering from alopecia, and rising technological advancement in dermatology science to address the female pattern baldness issue. It has been reported in women after menopause; hormonal imbalance is linked to hair loss.
The rising prevalence of androgenic alopecia, as well as a significant increase in alopecia specialty clinics and research institutes, drive market growth in North America.
North America is dominating the regional segment of the stem cell alopecia treatment market with a share of 35%. The major factors propelling market growth in the North American region are the rising prevalence of androgenic alopecia and the significant rise in specialty clinics and research institutes engaging in stem cell alopecia treatment. The existence of a technologically advanced dermatology segment and high disposable income further support the market's growth in the North American region.
Europe is the second-largest market, accounting for 30% of its share, owing to the increasing number of patients suffering from hair loss due to chemotherapy and radiation therapy. Strategic collaboration between academic research institutes and pharmaceutical companies will provide the necessary impetus to the research and development segment specializing in stem cell alopecia treatment. Asia Pacific accounts for 20% of the market and is expected to grow rapidly in the near future as the prevalence of female pattern baldness rises and per capita income rises.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is segmented by indication and by geography.
Biopharmaceutical companies highly involved in the stem cell alopecia treatment market are APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute, and the University of Southern California.
Key questions are answered in this report.
Which research institutes are developing stem cell technology to address androgenic alopecia problems?
What is KRT37, and how is it related to androgenic alopecia?
What are the global prevalence rate of alopecia and its ethnic variability?
Which stem are cells currently being employed to develop regenerative medicine to treat alopecia?
What is the etiology of male and female pattern baldness?
What will be the market performance of the Asia-Pacific region in the near future?
Frequently Asked Question:
The market for Stem Cell Alopecia Treatment Market is expected to reach USD$ XX in 2026.
The Stem Cell Alopecia Treatment Market is expected to see significant CAGR growth over the coming years, at 5.1%.
The report is forecasted from 2018 -2026.
The base year of this report is 2017.
APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute. are some of the major players in the global market
